This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Urea Cycle Disorder Market Size, Trends & Analysis - Forecasts to 2028 By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Others), By Enzyme Deficiency Type (Ornithine Transcarbamylas (OTC), Argininosuccinate Synthetase (citrullinemia) (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1), N-acetylglutamate Synthase (NAGS)), By Route of Administration (Oral, Injectable), By Region (North America, Asia Pacific, Central & South America, Europe, Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
The Global Urea Cycle Disorder Market is expected to be valued at USD 2.56 billion in 2023, and is projected to grow at a CAGR of 3.6% from 2023 to 2028.
The severity of the urea cycle disorder (UCD) is determined by the defective amount of protein. The presence of well-established companies, an increase in R&D spending by industry titans in the pharmaceutical sector and collaborations between pharmaceutical and biotech companies and research institutes are some of the factors influencing the global market for urea cycle disorders.
Rising prevalence of urea cycle disorders amongst both new-borns and geriatric patients is expected to propel the market. For instance, according to the National Library of Medicine’s report of 2021, out of every 35,000 live births, there are 113 new cases of urea cycle disorders in the United States. There are more than 149 patients in EU member states suffering from some form of the urea cycle disorder. According to a November 2021 StatPearls article, the prevalence of urea cycle disorder brought on by ornithine transcarbamylase deficiency is thought to be 1 in 140,000 individuals.
Furthermore, the market is expected to propel rapidly owing to strategic initiatives including collaborations, expansions, and acquisitions. For instance, in October 2021, Thoeris GmbH and Boehringer Ingelheim established a collaboration and licence agreement to research cutting-edge, first-in-class treatments for people with urea cycle diseases (UCDs). Such a collaboration will aid participants in utilising their knowledge and increasing the range of products they offer, thereby boosting the market.
As a result of these factors, it is anticipated that the global market would experience considerable growth throughout the study period. However, it is anticipated that the high cost of therapies may restrain market expansion during the forecast period.
The sodium phenylbutyrate segment is anticipated to be the fastest-growing segment in the market from 2023-2028, as it offers additional ammonia removal pathways and lowers ammonia levels. Furthermore, other factors associated with the growth of the segment is the increasing number of research projects linked with the usage of sodium phenylbutyrate and increasing awareness about the added advantages. For instance, in February 2022, the United States Patent and Trademark Office (USPTO) granted a new patent to Relief Therapeutics Holding SA and its joint venture partner, Acer Therapeutics, for specific claims regarding ACER-001 (sodium phenylbutyrate), who were conducting studies on ACER-001's multi-particulate dosage formulation for oral administration as a potential treatment for Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD).
The ornithine transcarbamylas (OTC) segment is expected to be the largest segment in the market from 2023-2028. The market is anticipated to grow significantly as a result of factors such as product approvals, rising number of R&D projects, and rising number of strategic initiatives taken by key market players to promote OTC. Ornithine transcarbamylase deficiency is one of the most prevalent disorders across the globe.
By route of administration, the global urea cycle disorder market is further bifurcated into oral and injectable. The oral segment is anticipated to be the largest segment in the market from 2023-2028 due to the widespread use of this method of medication administration and due to its added advantages such as ease of use, safety, high affordability, and usability as compared to the latter one. Moreover, formally medications in most of the cases, are taken orally to either have a local effect on the alimentary canal or a systemic effect after being absorbed into the bloodstream.
North America is expected to have the largest share in the market from 2023 to 2028. This is mainly due to the presence of key UCD related pharmaceutical players across U.S., the growth in the number of research and development projects associated with UCD drugs and nutrients, and the high prevalence of urea cycle disorders. It is also anticipated that increasing product launch activities and other growth strategic initiatives like alliances and mergers will aid in the market's expansion in the region.
Asia Pacific is expected to be the fastest growing segment in the global market. Some of the factors supporting the growth of this region are the presence of well-established pharma companies, rising expenditure for R&D activities by industry titans in the pharmaceutical sector, and partnerships between pharmaceutical, biotech companies and research institutes.
The key players covered in the global urea cycle disorder market report include Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories among others.
Please note: This is not an exhaustive list of companies profiled in the report.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
2.4 Data Metrics on Feed Stocks
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
4 GLOBAL UREA CYCLE DISORDER, BY TREATMENT TYPE
4.2 Urea Cycle Disorder: Treatment Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2022 & 2028
4.4.1 Amino Acid Supplements Market Estimates and Forecast, 2020-2028 (USD Million)
4.5.1 Sodium Phenylbutyrate Market Estimates and Forecast, 2020-2028 (USD Million)
4.7.1 Glycerol Phenylbutyrate Market Estimates and Forecast, 2020-2028 (USD Million)
4.7.1 Sodium Benzoate Market Estimates and Forecast, 2020-2028 (USD Million)
4.8.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)
5 GLOBAL UREA CYCLE DISORDER, BY ENZYME DEFICIENCY TYPE
5.2 Urea Cycle Disorder: Enzyme Deficiency Type Scope Key Takeaways
5.3 Revenue Growth Analysis, 2022 & 2028
5.4 Ornithine Transcarbamylas (OTC)
5.4.1 Ornithine Transcarbamylas (OTC) Market Estimates and Forecast, 2020-2028 (USD Million)
5.5 Argininosuccinate Synthetase (citrullinemia) (AS)
5.6.1 Arginase (AG) Market Estimates and Forecast, 2020-2028 (USD Million)
5.7 Argininosuccinate Lyase (AL)
5.7.1 Argininosuccinate Lyase (AL) Market Estimates and Forecast, 2020-2028 (USD Million)
5.8 Carbamoyl Phosphate Synthase (CPS1)
5.8.1 Carbamoyl Phosphate Synthase (CPS1) Market Estimates and Forecast, 2020-2028 (USD Million)
5.9 N-acetylglutamate Synthase (NAGS)
5.9.1 N-acetylglutamate Synthase (NAGS) Market Estimates and Forecast, 2020-2028 (USD Million)
6 GLOBAL UREA CYCLE DISORDER, BY ROUTE OF ADMINISTRATION
6.2 Urea Cycle Disorder: Route of Administration Scope Key Takeaways
6.3 Revenue Growth Analysis, 2022 & 2028
6.4.1 Oral Market Estimates and Forecast, 2020-2028 (USD Million)
6.5.1 Injectable Market Estimates and Forecast, 2020-2028 (USD Million)
7 GLOBAL UREA CYCLE DISORDER, BY REGION
7.2 North America Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.2.2 By Enzyme Deficiency Type
7.2.3 By Route of Administration
7.2.4.1 U.S. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.1.2 By Enzyme Deficiency Type
7.2.4.1.3 By Route of Administration
7.2.4.2 Canada Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.2.2 By Enzyme Deficiency Type
7.2.4.2.3 By Route of Administration
7.2.4.3 Mexico Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.3.2 By Enzyme Deficiency Type
7.2.4.3.3 By Route of Administration
7.3 Europe Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.2 By Enzyme Deficiency Type
7.3.3 By Route of Administration
7.3.4.1 Germany Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.1.2 By Enzyme Deficiency Type
7.3.4.1.3 By Route of Administration
7.3.4.2 U.K. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.2.2 By Enzyme Deficiency Type
7.3.4.2.3 By Route of Administration
7.3.4.3 France Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.3.2 By Enzyme Deficiency Type
7.3.4.3.3 By Route of Administration
7.3.4.4 Italy Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.4.2 By Enzyme Deficiency Type
7.2.4.4.3 By Route of Administration
7.3.4.5 Spain Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.5.2 By Enzyme Deficiency Type
7.2.4.5.3 By Route of Administration
7.3.4.6 Netherlands Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.7.2 By Enzyme Deficiency Type
7.2.4.7.3 By Route of Administration
7.3.4.7 Rest of Europe Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.7.2 By Enzyme Deficiency Type
7.2.4.7.3 By Route of Administration
7.4 Asia Pacific Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.2 By Enzyme Deficiency Type
7.4.3 By Route of Administration
7.4.4.1 China Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.1.2 By Enzyme Deficiency Type
7.4.4.1.3 By Route of Administration
7.4.4.2 Japan Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.2.2 By Enzyme Deficiency Type
7.4.4.2.3 By Route of Administration
7.4.4.3 India Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.3.2 By Enzyme Deficiency Type
7.4.4.3.3 By Route of Administration
7.4.4.4 South Korea Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.4.2 By Enzyme Deficiency Type
7.4.4.4.3 By Route of Administration
7.4.4.5 Singapore Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.5.2 By Enzyme Deficiency Type
7.4.4.5.3 By Route of Administration
7.4.4.6 Malaysia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.7.2 By Enzyme Deficiency Type
7.4.4.7.3 By Route of Administration
7.4.4.7 Thailand Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.7.2 By Enzyme Deficiency Type
7.4.4.7.3 By Route of Administration
7.4.4.8 Indonesia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.8.2 By Enzyme Deficiency Type
7.4.4.8.3 By Route of Administration
7.4.4.9 Vietnam Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.9.2 By Enzyme Deficiency Type
7.4.4.9.3 By Route of Administration
7.4.4.10 Taiwan Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.10.2 By Enzyme Deficiency Type
7.4.4.10.3 By Route of Administration
7.4.4.11 Rest of Asia Pacific Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.11.2 By Enzyme Deficiency Type
7.4.4.11.3 By Route of Administration
7.5 Middle East & Africa Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.5.2 By Enzyme Deficiency Type
7.5.3 By Route of Administration
7.5.4.1 Saudi Arabia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.1.2 By Enzyme Deficiency Type
7.5.4.1.3 By Route of Administration
7.5.4.2 U.A.E. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.2.2 By Enzyme Deficiency Type
7.5.4.2.3 By Route of Administration
7.5.4.3 Israel Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.3.2 By Enzyme Deficiency Type
7.5.4.3.3 By Route of Administration
7.5.4.4 South Africa Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.4.2 By Enzyme Deficiency Type
7.5.4.4.3 By Route of Administration
7.5.4.5.2 By Enzyme Deficiency Type
7.5.4.5.2 By Route of Administration
7.6 Central & South America Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.7.2 By Enzyme Deficiency Type
7.7.3 By Route of Administration
7.7.4.1 Brazil Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.7.4.1.2 By Enzyme Deficiency Type
7.7.4.1.3 By Route of Administration
7.7.4.2 Argentina Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.7.4.2.2 By Enzyme Deficiency Type
7.7.4.2.3 By Route of Administration
7.7.4.3 Chile Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)
7.7.4.3.2 By Enzyme Deficiency Type
7.7.4.3.3 By Route of Administration
7.7.4.4.2 By Enzyme Deficiency Type
7.7.4.4.3 By Route of Administration
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.4.1 Bausch Health Companies Inc.
8.4.1.1 Business Description & Financial Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2.1 Business Description & Financial Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
8.4.3.1 Business Description & Financial Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4.1 Business Description & Financial Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Ultragenyx Pharmaceutical
8.4.5.1 Business Description & Financial Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.7.1 Business Description & Financial Analysis
8.4.7.3 Products & Services Offered
8.4.7.4 Strategic Alliances between Business Partners
8.4.7 Arcturus Therapeutics, Inc.
8.4.7.1 Business Description & Financial Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8.1 Business Description & Financial Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Selecta Biosciences, Inc
8.4.9.1 Business Description & Financial Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10.1 Business Description & Financial Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
8.4.11.1 Business Description & Financial Analysis
8.4.11.3 Products & Services Offered
8.4.11.4 Strategic Alliances between Business Partners
9.1.2 Market Scope & SegSodium Phenylbutyratetation
9.2 Information ProcureSodium Phenylbutyratet
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2.1 Various Enzyme Deficiency Type of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.4 Discussion Guide for Primary Participants
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Product Sales
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
LIST OF TABLES
1 Global Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Mllion)
2 Amino Acid Supplements Market, By Region, 2020-2028 (USD Mllion)
3 Sodium Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)
4 Glycerol Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)
5 Sodium Benzoate Market, By Region, 2020-2028 (USD Mllion)
6 others Market, By Region, 2020-2028 (USD Mllion)
7 Global Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Mllion)
8 Ornithine Transcarbamylas (OTC) Market, By Region, 2020-2028 (USD Mllion)
9 Argininosuccinate Synthetase (citrullinemia) (AS) Market, By Region, 2020-2028 (USD Mllion)
10 Arginase (AG) Market, By Region, 2020-2028 (USD Mllion)
11 Argininosuccinate Lyase (AL) Market, By Region, 2020-2028 (USD Mllion)
12 Carbamoyl Phosphate Synthase (CPS1) Market, By Region, 2020-2028 (USD Mllion)
13 N-acetylglutamate Synthase (NAGS) Market, By Region, 2020-2028 (USD Mllion)
14 Global Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Mllion)
15 Oral Market, By Region, 2020-2028 (USD Mllion)
16 Injectable Market, By Region, 2020-2028 (USD Mllion)
17 Regional Analysis, 2020-2028 (USD Mllion)
18 North America Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
19 North America Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
20 North America Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
21 North America Urea Cycle Disorder, By Country, 2020-2028 (USD Million)
22 U.S Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
23 U.S Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
24 U.S Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
25 Canada Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
26 Canada Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
27 Canada Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
28 Mexico Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
29 Mexico Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
30 Mexico Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
31 Europe Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
32 Europe Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
33 Europe Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
34 Germany Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
35 Germany Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
36 Germany Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
37 UK Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
38 UK Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
39 UK Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
40 France Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
41 France Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
42 France Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
43 Italy Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
44 Italy Urea Cycle Disorder, By T Enzyme Deficiency Type Type, 2020-2028 (USD Million)
45 Italy Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
46 Spain Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
47 Spain Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
48 Spain Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
49 Rest Of Europe Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
50 Rest Of Europe Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
51 Rest of Europe Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
52 Asia Pacific Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
53 Asia Pacific Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
54 Asia Pacific Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
55 Asia Pacific Urea Cycle Disorder, By Country, 2020-2028 (USD Million)
56 China Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
57 China Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
58 China Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
59 India Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
60 India Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
61 India Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
62 Japan Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
63 Japan Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
64 Japan Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
65 South Korea Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
66 South Korea Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
67 South Korea Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
68 Middle East & Africa Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
69 Middle East & Africa Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
70 Middle East & Africa Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
71 Middle East & Africa Urea Cycle Disorder, By Country, 2020-2028 (USD Million)
72 Saudi Arabia Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
73 Saudi Arabia Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
74 Saudi Arabia Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
75 UAE Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
76 UAE Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
77 UAE Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
78 Central & South America Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
79 Central & South America Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
80 Central & South America Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
81 Central & South America Urea Cycle Disorder, By Country, 2020-2028 (USD Million)
82 Brazil Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)
83 Brazil Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)
84 Brazil Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)
85 Bausch Health Companies Inc.: Products & Services Offering
86 Recordati Rare Diseases: Products & Services Offering
87 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Products & Services Offering
88 Acer Therapeutics: Products & Services Offering
89 Ultragenyx Pharmaceutical: Products & Services Offering
90 AEGLEA BIOTHERAPEUTICS: Products & Services Offering
91 Arcturus Therapeutics, Inc. : Products & Services Offering
92 Orpharma Pty Ltd.: Products & Services Offering
93 Selecta Biosciences, Inc, Inc: Products & Services Offering
94 Abbott Laboratories: Products & Services Offering
95 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Urea Cycle Disorder Overview
2 Global Urea Cycle Disorder Value From 2020-2028 (USD Mllion)
3 Global Urea Cycle Disorder Share, By Treatment Type (2022)
4 Global Urea Cycle Disorder Share, By Enzyme Deficiency Type (2022)
5 Global Urea Cycle Disorder Share, By Route of Administration (2022)
6 Global Urea Cycle Disorder, By Region (Asia Pacific Market)
7 Technological Trends In Global Urea Cycle Disorder
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Urea Cycle Disorder
11 Impact Of Challenges On The Global Urea Cycle Disorder
12 Porter’s Five Forces Analysis
13 Global Urea Cycle Disorder: By Treatment Type Scope Key Takeaways
14 Global Urea Cycle Disorder, By Treatment Type Segment: Revenue Growth Analysis
15 Amino Acid Supplements Market, By Region, 2020-2028 (USD Mllion)
16 Sodium Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)
17 Glycerol Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)
18 Sodium Benzoate Market, By Region, 2020-2028 (USD Mllion)
19 Others Market, By Region, 2020-2028 (USD Mllion)
20 Global Urea Cycle Disorder: By Enzyme Deficiency Type Scope Key Takeaways
21 Global Urea Cycle Disorder, By Enzyme Deficiency Type Segment: Revenue Growth Analysis
22 Ornithine Transcarbamylas (OTC) Market, By Region, 2020-2028 (USD Mllion)
23 Argininosuccinate Synthetase (citrullinemia) (AS) Market, By Region, 2020-2028 (USD Mllion)
24 Arginase (AG) Market, By Region, 2020-2028 (USD Mllion)
25 Argininosuccinate Lyase (AL) Market, By Region, 2020-2028 (USD Mllion)
26 Carbamoyl Phosphate Synthase (CPS1) Market, By Region, 2020-2028 (USD Mllion)
27 N-acetylglutamate Synthase (NAGS) Market, By Region, 2020-2028 (USD Mllion)
28 Global Urea Cycle Disorder: By Route of Administration Scope Key Takeaways
29 Global Urea Cycle Disorder, By Route of Administration Segment: Revenue Growth Analysis
30 Oral Market, By Region, 2020-2028 (USD Mllion)
31 Injectable Market, By Region, 2020-2028 (USD Mllion)
32 Regional Segment: Revenue Growth Analysis
33 Global Urea Cycle Disorder: Regional Analysis
34 North America Urea Cycle Disorder Overview
35 North America Urea Cycle Disorder, By Treatment Type
36 North America Urea Cycle Disorder, By Enzyme Deficiency Type
37 North America Urea Cycle Disorder, By Route of Administration
38 North America Urea Cycle Disorder, By Country
39 U.S. Urea Cycle Disorder, By Treatment Type
40 U.S. Urea Cycle Disorder, By Enzyme Deficiency Type
41 U.S. Urea Cycle Disorder, By Route of Administration
42 Canada Urea Cycle Disorder, By Treatment Type
43 Canada Urea Cycle Disorder, By Enzyme Deficiency Type
44 Canada Urea Cycle Disorder, By Route of Administration
45 Mexico Urea Cycle Disorder, By Treatment Type
46 Mexico Urea Cycle Disorder, By Enzyme Deficiency Type
47 Mexico Urea Cycle Disorder, By Route of Administration
48 Four Quadrant Positioning Matrix
49 Company Market Share Analysis
50 Bausch Health Companies Inc.: Company Snapshot
51 Bausch Health Companies Inc.: SWOT Analysis
52 Bausch Health Companies Inc.: Geographic Presence
53 Recordati Rare Diseases: Company Snapshot
54 Recordati Rare Diseases: SWOT Analysis
55 Recordati Rare Diseases: Geographic Presence
56 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Company Snapshot
57 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): SWOT Analysis
58 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Geographic Presence
59 Acer Therapeutics: Company Snapshot
60 Acer Therapeutics: Swot Analysis
61 Acer Therapeutics: Geographic Presence
62 Ultragenyx Pharmaceutical: Company Snapshot
63 Ultragenyx Pharmaceutical: SWOT Analysis
64 Ultragenyx Pharmaceutical: Geographic Presence
65 Aeglea BioTherapeutics: Company Snapshot
66 Aeglea BioTherapeutics: SWOT Analysis
67 Aeglea BioTherapeutics: Geographic Presence
68 Arcturus Therapeutics, Inc. : Company Snapshot
69 Arcturus Therapeutics, Inc. : SWOT Analysis
70 Arcturus Therapeutics, Inc. : Geographic Presence
71 Orpharma Pty Ltd.: Company Snapshot
72 Orpharma Pty Ltd.: SWOT Analysis
73 Orpharma Pty Ltd.: Geographic Presence
74 Selecta Biosciences, Inc, Inc.: Company Snapshot
75 Selecta Biosciences, Inc, Inc.: SWOT Analysis
76 Selecta Biosciences, Inc, Inc.: Geographic Presence
77 Abbott Laboratories: Company Snapshot
78 Abbott Laboratories: SWOT Analysis
79 Abbott Laboratories: Geographic Presence
80 Other Companies: Company Snapshot
81 Other Companies: SWOT Analysis
82 Other Companies: Geographic Presence
The Global Urea Cycle Disorder Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Urea Cycle Disorder Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
